Resurgence of Chikungunya in Thailand Authors: Acharaporn Maksikharin, Usa Thisyakorn, Olarn Prommalikit Published: 2026 ABSTRACT Highlights•A total of 88,239 cases of chikungunya were reported in Thailand from 2008 to 2023, with a high peak of chikungunya outbreaks in Thailand between 2008-2009 and 2018-2020.•Chikungunya continues to be a concern year-round and peaks in the rainy season.•The disease affects people of all ages, primarily adults.•The vector transmission might become a global issue owing to the change in case distribution.•Ongoing surveillance, effective vector control, and reducing contact with the vectors are essential steps in preventing the disease.Keywords: Chikungunya, Resurgence, Thailand, Vector control, Outbreaks Introduction Chikungunya virus, an arbovirus belonging to the family Togaviridae genus Alphavirus, was first isolated in Tanzania in 1953 [1]. Aedes aegypti and Aedes albopictus are the major vectors in transmission. The incubation period is 2-12 days. The clinical manifestations range from asymptomatic to abrupt onset of fever, skin rash, and arthralgia or arthritis. Arthralgia is a prominent symptom in adults, mostly involving the small joints, which can be very severe and incapacitating, and tends to last 1-12 weeks [2]. The disease is endemic to Africa and Southeast Asia, with numerous outbreaks reported. The first outbreak in Asia was documented in Bangkok, Thailand in 1958 [3]. The chikungunya virus seemed to disappear after it had been circulating in Bangkok, Thailand for more than 20 years [4]. Since 2005, several Indian Ocean islands and India have experienced massive chikungunya outbreaks by the East/Central/South African genotypes [[5], [6], [7], [8]], whereas all earlier isolates from India during 1963-1973 were of the Asian genotype [[9], [10], [11]]. Other chikungunya outbreaks caused by the Asian genotype were frequently reported during 1960-2003 in many Southeast Asian countries, including India, Malaysia, Indonesia, Cambodia, Vietnam, Myanmar, Pakistan, the Philippines, and Thailand. Epidemics caused by re-emerging chikungunya virus were reported in Indonesia and Malaysia during 2005-2007 [12,13], and in India during 2006-2022 [6,8,10]. The outbreak investigations in northeastern and southeastern provinces in Thailand from 1991 to 1995 showed that all outbreaks occurred during the rainy season (June-August) [14]. The 3 most common clinical manifestations were fever with severe arthralgia and maculopapular rash. Both sexes and all age groups were affected. No deaths were reported. The outbreaks occurred in rural villagers, and all 3 larval indices, namely, Breteau index, House index, and Container index, were very high. Villagers from all affected areas mentioned that they had no experience of this disease, which suggests that chikungunya infection is a re-emerging disease in Thailand [14]. Therefore, we conducted this study to describe the epidemiological data of chikungunya infection in Thailand. Methods This is a retrospective, descriptive study, and the data of patients with chikungunya reported to the Center of Epidemiological Information, Bureau of Epidemiology, Ministry of Public Health, Thailand [15] from January 2008 to December 2023 were analyzed. Diagnosis of chikungunya fever adhered to the clinical and laboratory criteria as follows: Clinical criteria: acute onset of high fever and arthralgia/arthritis not explained by other medical conditions, with at least 1 of the following clinical manifestations: skin rashes, muscle ache, headache, periorbital pain, and skin bleeding. Laboratory criteria: at least 1 of the following tests in the acute phase: -virus isolation virus isolation -presence of viral ribonucleic acid by real-time polymerase chain reaction (RT-PCR) presence of viral ribonucleic acid by real-time polymerase chain reaction (RT-PCR) -presence of virus specific immunoglobulin (Ig) M antibodies by enzyme-linked immunosorbent assay method presence of virus specific immunoglobulin (Ig) M antibodies by enzyme-linked immunosorbent assay method -4-fold increase in IgG titers in samples collected at acute and convalescent stage by hemagglutination-inhibition test method, 10-14 days apart, including antibody titers more than 1:1280 for single serum. 4-fold increase in IgG titers in samples collected at acute and convalescent stage by hemagglutination-inhibition test method, 10-14 days apart, including antibody titers more than 1:1280 for single serum. Results During the study period, a total of 88,239 patients with chikungunya reported to the Bureau of Epidemiology, Ministry of Public Health, Thailand, with a high peak of chikungunya outbreaks in Thailand between 2008-2009 and 2018-2020 (Figure 1). In 2008, there were 2,494 cases of chikungunya, with a large increase in the number of cases to 52,057 in 2009. The morbidity rate increased from 3.95 to 82.03 cases per 100,000 population within 1 year. From 2010 to 2017, the number of cases decreased from 1,565 to 10 per year, with the morbidity rate ranging from 0.02 to 2.46 cases per 100,000 population. In 2018, the chikungunya outbreak was detected owing to the large number of cases (n = 3,580), with further increases to 13,121 and 11,331 cases in 2019 and 2020, respectively, and the morbidity rate increased to 5.4-19.73 cases per 100,000 population. There was one death reported in 2020, with a case fatality rate and mortality rate of 0.01% and 0.002 cases per 100,000 population, respectively. In 2021, the cases decreased to 671 and then slightly increased to 1,311 and 1,486 during 2022-2023, with the morbidity rate ranging from 1.01 to 2.25 cases per 100,000 population. Number of patients with chikungunya in Thailand between 2008 and 2023. The patients were primarily from the southern region of Thailand during 2008-2019. In 2020, most patients lived in the northern region, followed by the central region. During 2021-2023, the patients were primarily from the central region (Figure 2). Chikungunya disease can be observed in all age groups, with the peak age group in adults without sex predilection (Figure 3). The disease was observed all year round, with higher incidence during the rainy season from May onward (Figure 4). There was only one death case in 2020; however, the high morbidity, with severe arthralgia persisting for several months, weakened the patients mentally and physically. Distribution of patients with chikungunya from different regions in Thailand between 2008 and 2023. Age distribution of patients with chikungunya in Thailand between 2008 and 2023. Seasonal distribution of patients with chikungunya in Thailand between 2008 and 2023. Discussion The first outbreak of chikungunya disease in Asia was documented in Bangkok, Thailand in 1958, and the disease was common in Bangkok, Thailand between 1962 and 1964, after which it decreased to an extremely low level. The reasons for the marked reduction in chikungunya transmission in Bangkok, Thailand over the past decades are obscure given the known vector species, Aedes aegypti and Aedes albopictus, are obviously present in abundance as evidenced by continued high dengue transmission rates [3]. Our study has shown that from 2008 to 2019, chikungunya outbreak occurred primarily in southern Thailand during the rainy season. All age groups were affected, with the peak age group in adults without sex predilection, as observed in the previous outbreak investigation during 1991-1995 [14]. The sudden onset of very high fever along with rash and severe arthralgia, especially in the small joints of hands and toes, is characteristic of the disease because the viral entry receptors, including matrix remodeling-associated protein 8, are expressed on fibroblasts, epithelial cells, and synovial cells [16]. Arthralgia is the primary symptom in adults, mostly involving the small joints, which can be very severe and incapacitating and tends to last from 1 to 12 weeks. In general, children have a milder form of the disease than do adults. Chikungunya disease must be distinguished from dengue disease because although these diseases share primary clinical manifestations, shock or severe hemorrhage is rarely observed in chikungunya disease [17,18]. Infants with chikungunya fever may have peripheral cyanosis and vesiculobullous lesions; next, peeling and hypopigmentation or hyperpigmentation develop [19]. During the outbreak in La Réunion, miscarriages in pregnant women before 22 weeks of gestation were attributed to the chikungunya infection by positive RT-PCR test results for chikungunya virus in amniotic fluid and placenta. Mother-to-child transmission has been observed during the intrapartum period between 4 days before and 1 day after delivery. The vertical transmission rate was 48.7%. In neonates, symptoms developed on days 3 to 7, including fever, skin rash, peripheral edema, and feeding problems; 39% of cases had complications including encephalopathy, hemodynamic disorders, and hemorrhagic syndrome [20,21]. The infrequent manifestations that were attributed to death in the outbreak in the Indian Ocean islands were encephalopathy, acute hepatitis, and acute myocarditis. The severity of chikungunya infection might relate to a previously mentioned chikungunya viral mutation that caused many outbreaks in the previous 4 years [22]. Diagnostic techniques to confirm chikungunya infection include viral isolation, molecular techniques (RT-PCR to detect viral ribonucleic acid), serology test by the indirect immunofluorescent method, enzyme-linked immunosorbent assay, hemagglutination-inhibition test, and neutralization techniques. Single serum for the anti-chikungunya immunoglobulin M antibody test is most widely used, which may not be appropriate to confirm diagnosis owing to its cross-reactivity with other alpha viruses, and it cannot differentiate between recent past and acute infection given anti-chikungunya immunoglobulin M antibody is present after the onset of symptoms and persists for several months. Besides, its sensitivity was only 4% to 22%, and after 1 week, it increased to more than 80%. Serodiagnosis should be considered on an increase in anti-chikungunya antibody being shown between the acute and convalescent phase sera [23]. Treatment of chikungunya disease is mainly supportive. The mortality rate is low; however, patients—especially older adults and those with pre-existing joint conditions—may experience severe joint pain that can persist for several months [24]. These individuals have a higher likelihood of prolonged disease, characterized by fluctuations and debilitating symptoms due to a dual mechanism involving viral persistence from ineffective viral clearance and ongoing inflammatory immune activation [16]. Our study did not report the genomic sequences of chikungunya, but there are published genetic and exomic characterizations from Thailand during the 2008-2009 and 2018-2020 outbreaks. The viral genomes from these recent outbreaks differed from the previous outbreaks in Thailand but were similar to the genomic sequences of chikungunya virus African strains with the A226V mutation [[24], [25], [26], [27], [28]]. The presence of a mutation in the viral gene encoding the envelope protein at position 226 (E1: A226V) enhanced the replication efficiency of chikungunya virus in Aedes albopictus; thus, it facilitated viral transmission to humans [5,23]. Moreover, previous studies have noted a higher incidence of symptomatic cases with African strains than with Asian strains [29]. It has been documented that chikungunya virus has spread from Africa to Asia, notably causing outbreaks in India [[6], [7], [8], [9], [10]]. Since then, numerous outbreaks involving African strains have occurred in Réunion Island and Europe, whereas outbreaks in the Americas have involved Asian strains. Occasionally, an African strain case was reported in northern Brazil, which subsequently experienced epidemics [29]. The virus's adaptive evolution through mutations in its proteins enhances its ability to infect vectors and increases transmission rates. Infected humans, particularly during early or asymptomatic stages, serve as reservoirs, enabling virus transmission from person to person through mosquito bites—known as human-mosquito-human transmission. High international travel further facilitates the global spread and outbreaks [16,29]. Warm, humid climates promote vector reproduction, distribution, and activity, as observed during the 2010 outbreak in southeastern and southwestern China. Climate change, such as global warming, could trigger unpredictable future outbreaks worldwide, including in Western countries and the United States. Because vector activity depends on favorable environmental conditions, outbreaks typically occur during the rainy season [16]. Thailand's vulnerability to chikungunya persists owing to its tropical climate, high rainfall, strategic location, large susceptible population, porous borders with significant travel from epidemic areas, and the presence of primary vectors—Aedes aegypti and Aedes alobopictus—which are most active during the post-monsoon period when vector density peaks. Preventive measures include mosquito control and minimizing vector contact [30,31], community education, early warning systems, elimination of breeding sites, environmental management, use of chemical, biological, and innovative vector control methods, and personal protection, especially for high-risk groups [16,29]. Surveillance, encompassing entomological and xenosurveillance [16], is crucial for controlling chikungunya. This includes outbreak investigation, incidence tracking, disease burden assessment, strain distribution analysis, control strategy evaluation, and ongoing monitoring of vector density and larval habitats [15,16,29]. In the absence of a vaccine, high vigilance for autochthonous transmission and stringent vector control, coupled with a swift public health response, are essential. Several vaccine candidates are under ongoing development, including formalin-inactivated, subunit, live attenuated, recombinant virus-vectored, virus-like particle, chimeric, and nucleic acid vaccines [32,33]. Our study has some limitations: 1. epidemiologic data from Thailand may be inconsistent or underestimated owing to differences in diagnostic tools, reporting practices, and health care settings, and 2. the African strains of chikungunya virus were identified through epidemiological surveillance as sentinel samples during outbreaks; not all cases underwent genomic sequencing. Conclusions Thailand remains at risk of chikungunya outbreaks owing to a highly susceptible population, a porous border with high travel volumes from epidemic areas, and high vector density. In the absence of a vaccine, effective vector control, including educating and engaging the local community, elimination of breeding sites, managing the environment, using chemical, biological, and innovative vector birth control, personal and household protection, especially susceptible populations, and routine surveillance, particularly entomological surveillance and xenosurveillance, should be maintained along with a swift public health response. CRediT authorship contribution statement Acharaporn Maksikharin: Data curation, Investigation, Visualization, Writing – original draft. Usa Thisyakorn: Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – review & editing. Olarn Prommalikit: Conceptualization, Formal analysis, Investigation, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors have no competing interests to declare. Acknowledgments Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Ethical approval This study was performed in line with the principles of the Declaration of Helsinki and ethical approval from the Ethics Review Committee, Srinakharinwirot University (exemption review). Data availability The data are available from the corresponding author on reasonable request. Use of Artificial Intelligence (AI) tools Not applicable. References Associated Data Data Availability Statement The data are available from the corresponding author on reasonable request.